Article Sidebar
Published:
Mar 14, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Xuebijing injection alleviates liver injury in patients with hepatocellular carcinoma by inhibiting inflammatory response after transarterial chemoembolization
Abstract
Purpose: To study the influence of Xuebijing (XBJ) injection on patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE), and to elucidate the underlying mechanism of action.
Methods: Thirty-nine HCC patients were retrospectively analyzed. They were assigned to 3 groups: negative group which received no XBJ injection, low-dose XBJ group given XBJ injection (50 ml), and high-dose XBJ group given 100 mL of XBJ injection. Peripheral blood was separately collected and
analyzed on the first day after admission and TACE.
Results: TACE led to liver damage in HCC patients, with increased serum activities of ALT and AST, and total bilirubin (tBLB). Moreover, TACE elevated white blood cells, neutrophil count, C-reactive protein (CRP) and expression levels of inflammation cytokines. In the groups treated with XBJ injection,
there were dose-dependent mitigation of liver dysfunction, and reduced levels of inflammatory cytokines, when compared with the negative group. However, XBJ injection did not affect myelosuppression or regulatory T cells.
Conclusion: XBJ dose-dependently decreases liver injury in HCC patients after TACE by suppressing inflammatory response. Thus, XBJ may exert hepatoprotective effect on HCC after TACE in humans in clinical practice.
